Lectin-like Oxidized Low-Density Lipoprotein (LDL) Receptor (LOX-1): A Chameleon Receptor for Oxidized LDL

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• Receptor Biology

Background:

• The lectin-like oxidized LDL receptor 1 (LOX-1) is a key receptor for oxidized low-density lipoprotein (oxLDL), primarily expressed on endothelial cells.
• LOX-1 is a 52 kDa type II transmembrane protein belonging to the C-type lectin family, featuring distinct intracellular and extracellular domains.

Purpose of the Study:

• To elucidate the multifaceted roles of LOX-1 in atherogenesis and its potential as a therapeutic target.
• To explore the impact of LOX-1 gene polymorphisms and splicing variants on cardiovascular disease susceptibility.

Main Methods:

• Analysis of LOX-1 structure and function as a receptor for oxLDL.
• Investigation of LOX-1 signaling pathways, including NFκB activation and its role in inflammation.
• Examination of the influence of anti-inflammatory molecules like IL-10 on LOX-1 activity.
• Study of LOX-1 gene polymorphisms and splicing variants (e.g., LOXIN) in relation to myocardial diseases.

Main Results:

• LOX-1 exhibits bifunctional activity, promoting pro-atherogenicity via NFκB signaling or acting atheroprotectively through oxLDL uptake modulated by IL-10.
• Different oxidation states of LDL elicit distinct responses upon LOX-1 activation.
• Polymorphisms in LOX-1 genes are strongly linked to increased susceptibility to myocardial diseases.
• The LOXIN splicing variant dimerizes with native LOX-1, conferring cellular protection against oxLDL damage.

Conclusions:

• LOX-1 is a critical mediator in cardiovascular pathology with both detrimental and protective functions.
• LOX-1 genetic variations represent significant risk factors for myocardial diseases.
• LOX-1 emerges as a promising therapeutic target in regenerative medicine for cardiovascular conditions.